News

IP 101 – Patent Infringement

on December 3, 2017

There is increasing pressure on Canadian universities to produce research with translational or commercial potential. In this regard, researchers typically work with the technology transfer offices at their university to identify technologies with commercial applicability and if appropriate, secure patent protection for such technologies. Rarely have academic institutions been concerned with infringing third party patents, assuming the nature of their work immunized them from such concerns. For the reasons discussed below, academic institutions may wish to pay greater attention to patent infringement issues and be mindful of using patented inventions in their research to avoid incurring potential legal liability as the shift towards commercial research continues.

Read more
ecommIP 101 – Patent Infringement

Moral rights – waived

on September 15, 2017

If you are an inventor who is looking for help from the University or other potential investors to commercialize your invention, you will likely come across an assignment agreement asking you to transfer ownership of the intellectual property rights associated with your invention in exchange for funding or marketing services.

However, upon reading such an agreement you may also notice that you are being asked to waive your “moral rights” to your invention under the Copyright Act. This may catch you off guard and question whether you are being asked to abandon your moral or ethical principles for the sake of marketing your invention.

Read more
ecommMoral rights – waived

Biologic is the beginning

on August 18, 2017

Biologics and its landscape in Canada: The pharmaceutical industry is currently a multi-billion dollar industry that continues to grow each year. In Canada, biologics (or biologic drugs) make up about 14% of drug spending at a cost of $3 billion a year. With the expiration of many key patents for top-selling biologics in recent years, the interest in producing ‘generic’ biologics (or “biosimilars”) has increased. Even if you are not concerned about inventing around existing patents, it may still be useful to know how biologics are classified by the Patent Office and the fact that the existence of biosimilars in the drug market significantly lowers the cost of these relatively expensive drugs.

Read more
ecommBiologic is the beginning

Who put the IP in CRISPR?

on July 7, 2017

“CRISPR” is often heralded as the breakthrough medical technology of the decade that will revolutionize the biotech and healthcare industry. However, the technology is currently in the midst of a longstanding IP ownership war between MIT/Harvard’s Broad Institute and the University of California-Berkeley. Although this war is between two U.S. entities, there are far-reaching implications for anybody who wishes to use CRISPR, such as the many Canadian researchers and scientists who are eager to accelerate their own research.

Read more
ecommWho put the IP in CRISPR?

Profiting from secrets

on June 9, 2017

What is the value of a secret? The value of some secrets is in their disclosure to the highest bidder, like celebrity gossip and paparazzi photos. Other secrets have a functional value which can be realized indefinitely, like the recipe for Coca-Cola, or a secret manufacturing process that is more efficient than the competitors’. What all secrets have in common, though, is that they lose their value the moment they are inadvertently disclosed.

The value of a secret is in its exploitation. This can be accomplished in two ways: by keeping the secret a secret (and utilizing it), or by disclosing it to someone in exchange for something.

Read more
ecommProfiting from secrets

London leads provincial technology transfer and R&D partnership efforts in Asia

on June 5, 2017

Financial ripples from a successful, London-led business development initiative in Asia may soon be felt across the province.

In 2011, WORLDiscoveries Asia – a partnership among Western University, Robarts Research Institute and Lawson Health Research Institute – became Canada’s first technology transfer initiative to establish a physical presence in China, as it opened offices in Hong Kong and, eventually, Nanjing, which is London’s ‘sister city.’

Supported by $300,000 from the Ontario government, the initiative has now grown to the point of leveraging its expertise to promote, facilitate and manage technology-based alliances with Asian organizations as a service to other research institutions, NGOs and small- and medium-sized enterprises (SMEs) across the province.

Read more
ecommLondon leads provincial technology transfer and R&D partnership efforts in Asia

Keeping your secret a secret

on May 12, 2017

Secrecy is an important part of protecting your intellectual property. As we have discussed previously in “The first rule of inventor fight club…” and Publishing and patenting, maintaining the secrecy of your inventions is pivotal to acquiring a patent. In the case of trade secrets, the secrecy itself is the only thing that is maintaining your trade secret’s value. However, sometimes you need to be able to share your secret with others – such as researchers at another institution or external developers. How can you do that without endangering your secret and the future patentability of your invention?

Read more
ecommKeeping your secret a secret

Lawson Impact Awards celebrates research making a difference

on May 2, 2017

Off­site – With nearly 300 guests in attendance, health research was celebrated at the fourth annual Lawson Impact Awards on Wednesday, April 19 at the London Convention Centre.

The Lawson Impact Awards celebrates hospital-based research that makes a difference by advancing scientific knowledge and applying it directly to patient care. With awards in seven categories, the annual event honours Lawson scientists, staff, trainees and partners who demonstrate excellence.

Read more
ecommLawson Impact Awards celebrates research making a difference

Firm to 3D print body repair parts

on April 21, 2017
Matt Parkes handles a bleach-white model of a skull, held together by what looks like steel plates fastened around its eye socket.

It is a model of a skull rebuilt after a massive car crash. Parkes, the technical manager at Adeiss, London’s newest medical devices company, credits the plates with enabling the rebuilding of the face and the life of the person to whom it belongs.

Now, that technology is available in London. Adeiss will be unveiled at a news conference today as a new business that will provide 3D printing solutions to the health-care sector, including surgeons who need a plate for a skull fracture.

Read more
ecommFirm to 3D print body repair parts

What use is that?

on April 7, 2017

In order to acquire a patent for an alleged invention, it must be novel and unobvious and useful.

Two of our previous articles, “The first rule of inventor fight club” and “Publishing and patenting” have focused on the novelty requirement of patentability.

Another previous article, “Is it obvious? That’s a tricky question”, focused on the unobviousness requirement. This article will explore the “useful” requirement.

Read more
ecommWhat use is that?